It can be hypothesized that breast cancer resistant to CDK4/6 inhibitors acquires cross-resistance to chemotherapeutic agents and reduces post-progression survival after CDK4/6 inhibitor therapies. The gene discussed is CDK4; the disease is breast cancer.